Investor/Media Center

print page



Welcome to Palatin's Investor Relations Information Site. We are pleased to provide you with information regarding Palatin Technologies' financial highlights. For your convenience, we provide a library of press releases, events and webcasts, as well as prefiltered links to the EDGAR database.

Palatin at-a-Glance:

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin’s primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD).

Latest News:


Financial Snapshot:

(as of 12/31/14)  
NYSE MKT symbol: PTN
Shares outstanding:  
   Common: 41.6 million
   Fully diluted: 163.3 million
52-wk price range: $0.59 - $1.50
Market cap: $30.4 million
Employees: 20
Headquarters: Cranbury, NJ
Fiscal year end: June 30th
CEO: Dr. Carl Spana
CFO/COO: Stephen T. Wills


Portions of this website may contain forward-looking statements concerning the future business, operating results and/or financial condition of Palatin Technologies, Inc. as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of uncertainties that could cause actual performance and results to differ materially from those anticipated by such forward-looking statements. For more information about these risks, please see the documents that the Company files from time to time with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and other periodic reports. Any forward-looking statements on this website are based on current expectations, and Palatin Technologies assumes no obligation to update them.